Compare REFI & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REFI | LCTX |
|---|---|---|
| Founded | 2021 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.1M | 251.4M |
| IPO Year | 2021 | 1996 |
| Metric | REFI | LCTX |
|---|---|---|
| Price | $9.35 | $1.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $15.13 | $5.50 |
| AVG Volume (30 Days) | 190.0K | ★ 1.5M |
| Earning Date | 11-10-2026 | 11-05-2026 |
| Dividend Yield | ★ 20.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $48,857,628.00 | $14,556,000.00 |
| Revenue This Year | $0.76 | $4.38 |
| Revenue Next Year | $7.89 | $10.80 |
| P/E Ratio | $16.50 | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $8.76 | $0.88 |
| 52 Week High | $13.49 | $2.09 |
| Indicator | REFI | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.14 | 52.82 |
| Support Level | N/A | $0.89 |
| Resistance Level | $10.97 | $1.05 |
| Average True Range (ATR) | 0.26 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 50.00 | 74.16 |
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.